Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 The ODYSSEY DM-DYSLIPIDEMIA trial: confirming the benefits of alirocumab in diabetic mixed dyslipidemia.

Literature DB >> 29285510

The ODYSSEY DM-DYSLIPIDEMIA trial: confirming the benefits of alirocumab in diabetic mixed dyslipidemia.

Paul Chan¹, Li Shao², Brian Tomlinson^3,4, Zhong-Min Liu⁵.

Abstract

Entities: Chemical Disease

Year: 2017 PMID： 29285510 PMCID： PMC5733316 DOI： 10.21037/atm.2017.10.26

Source DB: PubMed Journal: Ann Transl Med ISSN： 2305-5839

Keyword Cloud
References

× No keyword cloud information.

25 in total

1. Alirocumab for hyperlipidemia: physiology of PCSK9 inhibition, pharmacodynamics and Phase I and II clinical trial results of a PCSK9 monoclonal antibody.

Authors: Eli M Roth; Philip Diller
Journal: Future Cardiol Date: 2014-03

2. Efficacy and safety of alirocumab in insulin-treated patients with type 1 or type 2 diabetes and high cardiovascular risk: Rationale and design of the ODYSSEY DM-INSULIN trial.

Authors: B Cariou; L A Leiter; D Müller-Wieland; G Bigot; H M Colhoun; S Del Prato; R R Henry; F J Tinahones; A Letierce; L Aurand; J Maroni; K K Ray; M Bujas-Bobanovic
Journal: Diabetes Metab Date: 2017-03-24 Impact factor: 6.041

Review 3. 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents.

Authors: Donald M Lloyd-Jones; Pamela B Morris; Christie M Ballantyne; Kim K Birtcher; David D Daly; Sondra M DePalma; Margo B Minissian; Carl E Orringer; Sidney C Smith
Journal: J Am Coll Cardiol Date: 2016-04-01 Impact factor: 24.094

4. 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR).

Authors: Alberico L Catapano; Ian Graham; Guy De Backer; Olov Wiklund; M John Chapman; Heinz Drexel; Arno W Hoes; Catriona S Jennings; Ulf Landmesser; Terje R Pedersen; Željko Reiner; Gabriele Riccardi; Marja-Riita Taskinen; Lale Tokgozoglu; W M Monique Verschuren; Charalambos Vlachopoulos; David A Wood; Jose Luis Zamorano
Journal: Atherosclerosis Date: 2016-09-01 Impact factor: 5.162

Review 5. Alirocumab for the treatment of hypercholesterolemia.

Authors: Brian Tomlinson; Miao Hu; Yuzhen Zhang; Paul Chan; Zhong-Min Liu
Journal: Expert Opin Biol Ther Date: 2017-03-20 Impact factor: 4.388

Review 6. Triglyceride-Rich Lipoproteins and Atherosclerotic Cardiovascular Disease: New Insights From Epidemiology, Genetics, and Biology.

Authors: Børge G Nordestgaard
Journal: Circ Res Date: 2016-02-19 Impact factor: 17.367

7. Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.

Authors: S Matthijs Boekholdt; Benoit J Arsenault; Samia Mora; Terje R Pedersen; John C LaRosa; Paul J Nestel; R John Simes; Paul Durrington; Graham A Hitman; K M A Welch; David A DeMicco; Aeilko H Zwinderman; Michael B Clearfield; John R Downs; Andrew M Tonkin; Helen M Colhoun; Antonio M Gotto; Paul M Ridker; John J P Kastelein
Journal: JAMA Date: 2012-03-28 Impact factor: 56.272